<DOC>
	<DOCNO>NCT01133977</DOCNO>
	<brief_summary>Primary : - Phase Ib : To define safety , tolerability maximum tolerate dose ( MTD ) lenvatinib administer combination dacarbazine . - Phase II : To evaluate safety tolerability lenvatinib administer combination dacarbazine , compare dacarbazine alone . Secondary : -Phase II : To make preliminary assessment efficacy lenvatinib administer combination dacarbazine , compare dacarbazine alone .</brief_summary>
	<brief_title>E7080 ( Lenvatinib ) Combination With Dacarbazine Versus Dacarbazine Alone First Line Therapy Patients With Stage IV Melanoma</brief_title>
	<detailed_description>Safety assess monitor record treatment emergent adverse event ( AEs ) serious adverse event ( SAEs ) ; regular monitoring clinical laboratory parameter ; periodic measurement vital sign electrocardiogram ( ECGs ) ; dose limit toxicity ; performance physical examination ; concomitant medication procedure .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>1 . Patients histologicallyconfirmed metastatic melanoma ( Stage IV , American Joint Committee Cancer ( AJCC ) ) . 2 . No prior cytokine , chemotherapy , target therapy Stage IV melanoma . 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . 4 . Life expectancy great equal 3 month . 5 . At least 1 site measurable disease RECIST 1.1 . 6 . Adequate hematologic , renal , liver , coagulation system function define laboratory value perform within 21 day prior initiation dose . 7 . Blood pressure must wellcontrolled ( less equal 140/90 mmHg screening ) without antihypertensive medication . Patients must history hypertensive crisis hypertensive encephalopathy . 1 . Known central nervous system ( CNS ) lesion , except asymptomatic , nonprogressive , treat brain metastasis . Treatment brain metastasis must complete least 4 week prior Day 1 may include whole brain radiotherapy ( WBRT ) , radiosurgery [ RS ; Gamma Knife , linear accelerator ( LINAC ) , equivalent ] combination deem appropriate treating physician . Dexamethasone must discontinue least 3 week prior Day 1 . Patients CNS metastasis treat neurosurgical resection brain biopsy perform within 3 month prior Day 1 exclude . 2 . Lactate dehydrogenase great equal 2.0 x upper limit normal ( ULN ) . 3 . Subjects proteinuria great 1+ urine dipstick test undergo 24hour urine collection quantitative assessment proteinuria . Subjects 24hour urine protein great equal 1 g/24 hour ineligible . 4 . Pregnant , breastfeeding , refuse double barrier contraception , oral contraceptive avoidance pregnancy measure . 5 . Other active malignancy . 6 . History know carcinomatous meningitis . 7 . History known ocular melanoma . 8 . Are currently receive treatment tumor ( include palliative radiotherapy ) aside control symptom . 9 . Received treatment another clinical study within 30 day prior commence study treatment patient recover side effect investigational drug grade le equal 1 , except alopecia . 10 . Received radiotherapy within 30 day prior commence study treatment recover side effect radiationrelated toxicity grade less equal 1 , except alopecia . 11 . Serious nonhealing wound , ulcer , bone fracture , undergone major surgical procedure , open biopsy , significant traumatic injury within 28 day prior commence study treatment . Minor surgery Portacath placement skin biopsy permit great equal 7 day pass . 12 . History bleed diathesis coagulopathy . 13 . Current use anticoagulant Vitamin K antagonist , unfractionated heparin , low molecular weight heparin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>